Page 123 - 《中国药房》2025年18期
P. 123

[ 6 ]  杨丽,罗太敏,秦先涛,等. 贝伐珠单抗联合紫杉醇类化                       cn/guideline/21560.
              疗药物治疗铂耐药复发性卵巢癌的 Meta 分析[J]. 中国                 [19]  PEREZ-FIDALGO  J  A,GÁLVEZ-MONTOSA  F,
              临床药学杂志,2023,32(6):436-443.                          GUERRA E M,et al. SEOM-GEICO clinical guideline on
          [ 7 ]  贺哲,张杰,翁雨雄,等. DRG支付方式改革下大型公立                      epithelial  ovarian  cancer:2023[J].  Clin  Transl  Oncol,
              医院临床路径实施策略分析[J]. 中国医院管理,2024,44                     2024,26(11):2758-2770.
              (4):70-73.                                     [20]  Belgian Health Care Knowledge Centre. Ovarian cancer:
          [ 8 ]  BROUWERS M C,KHO M E,BROWMAN G P,et al.          diagnosis,treatment and follow-up[EB/OL].[2025-08-02].
              AGREE  Ⅱ :advancing  guideline  development,reporting   https://kce.fgov.be/en/publications/all-reports/ovarian-cancer-
              and evaluation in health care[J]. CMAJ,2010,182(18):  diagnosis-treatment-and-follow-up.
              E839-E842.                                     [21]  SUH D H,CHANG S J,SONG T,et al. Practice guide‐
          [ 9 ]  廖少君,詹吉恒,侯宇,等. 神经根型颈椎病临床实践指                       lines for management of ovarian cancer in Korea:a Korean
              南和专家共识方法学与报告质量评价[J]. 中国中西医结                         Society of Gynecologic Oncology consensus statement[J].
              合杂志,2024,44(10):1197-1205.                          J Gynecol Oncol,2018,29(4):e56.
          [10]  张福强,胡紫腾,张钰菁,等. 中成药临床实践指南制定                   [22]  蓝春燕,王雅卓,张师前. 铂敏感复发性卵巢癌诊治中国
              方法(八):基于AGREE Ⅱ和RIGHT的中成药临床实践                       专家共识:2023 年版[J]. 中国实用妇科与产科杂志,
              指南质量评价[J]. 中医杂志,2024,65(2):185-201.
                                                                  2023,39(9):935-942.
          [11]  关舒予,常天瀛,王健康,等 . 基于 AGREE Ⅱ对急性心
                                                             [23]  卢淮武,温灏,邹冬玲,等. 卵巢上皮性癌一线化疗中国
              肌梗死临床指南的质量评价[J]. 中国实验方剂学杂志,
                                                                  专家共识[J]. 实用妇产科杂志,2022,38(8):582-588.
              2025,31(10):201-209.
                                                             [24]  张德普,孙阳,张师前,等. 黏液性卵巢癌诊断与治疗中
          [12]  National Comprehensive Cancer Network. NCCN clinical
                                                                  国专家共识:2021 年版[J]. 中国微创外科杂志,2021,21
              practice  guidelines  in  oncology:ovarian  cancer  continue
                                                                 (7):577-588.
              including  fallopian  tube  cancer  and  primary  peritoneal
                                                             [25]  刘军秀,陈怡李,高国兰,等. 老年卵巢癌诊治中国专家
              cancer:version 1.2025[EB/OL].[2025-03-15]. https://guide.
                                                                  共识[J]. 现代肿瘤医学,2024,32(24):4569-4579.
              medlive.cn/guideline/34514.
                                                             [26]  LEDERMANN J A,MATIAS-GUIU X,AMANT F,et al.
          [13]  中国临床肿瘤学会 . 卵巢癌诊疗指南:2024[EB/OL].
                                                                  ESGO-ESMO-ESP  consensus  conference  recommenda‐
              [2025-03-15]. https://meeting.csco.org.cn/pdf/web/viewer.
                                                                  tions on ovarian cancer:pathology and molecular biology
              html?file=/Upload/Periodical/20241225021207.pdf.
                                                                  and early,advanced and recurrent disease[J]. Ann Oncol,
          [14]  TOKUNAGA  H,MIKAMI  M,NAGASE  S,et  al.  The
                                                                  2024,35(3):248-266.
              2020  Japan  Society  of  Gynecologic  Oncology  guidelines
                                                             [27]  蓝春燕,董延磊,张师前,等. 低级别浆液性卵巢癌诊治
              for the treatment of ovarian cancer,fallopian tube cancer,
                                                                  中国专家共识:2024 年版[J]. 中国癌症防治杂志,2025,
              and primary peritoneal cancer[J]. J Gynecol Oncol,2021,
                                                                  17(1):11-20.
              32(2):e49.
                                                             [28]  邵丽华,张秋宁,田金徽,等. 食管癌临床指南和共识的
          [15]  HIRTE  H,POON  R,YAO  X  M,et  al.  Neoadjuvant  and
              adjuvant systemic therapy for newly diagnosed stage Ⅱ-   质量评价[J]. 中国循证医学杂志,2020,20(5):593-603.
              Ⅳ  epithelial  ovary,fallopian  tube,or  primary  peritoneal   [29]  胡菲菲,何俊勇,何礼霞,等. 2014—2018年中国宫颈癌
              carcinoma:a  systematic  review[J].  Curr  Oncol,2022,29  临床实践指南的方法学质量评价[J]. 中国循证医学杂
              (1):231-242.                                        志,2019,19(8):989-993.
          [16]  GONZÁLEZ-MARTÍN A,HARTER P,LEARY A,et al.    [30]  田昕彤,马腾,孙璇,等. 老年高血压临床指南现状分析
              Newly diagnosed and relapsed epithelial ovarian cancer:  及质量评价[J]. 中国全科医学,2022,25(34):4259-
              ESMO clinical practice guideline for diagnosis,treatment   4266,4285.
              and follow-up[J]. Ann Oncol,2023,34(10):833-848.  [31]  王吉耀. 从循证医学观点评估和应用临床指南[J]. 中华
          [17]  MOSS  E,TAYLOR  A,ANDREOU  A,et  al.  British       消化杂志,2004,24(7):385-386.
              Gynaecological Cancer Society(BGCS)ovarian,tubal and   [32]  陈耀龙,罗旭飞,王吉耀,等. 如何区分临床实践指南与
              primary  peritoneal  cancer  guidelines:recommendations   专家共识[J]. 协和医学杂志,2019,10(4):403-408.
              for practice update 2024[J]. Eur J Obstet Gynecol Reprod   [33]  MUTCH D G,PRAT J. 2014 FIGO staging for ovarian,
              Biol,2024,300:69-123.                               fallopian  tube  and  peritoneal  cancer[J].  Gynecol  Oncol,
          [18]  Scottish  Intercollegiate  Guidelines  Network.  SIGN  135:   2014,133(3):401-404.
              management of epithelial ovarian cancer:a national clini‐     (收稿日期:2025-04-01  修回日期:2025-08-26)
              cal guideline[EB/OL].[2025-03-15]. https://guide.medlive.                           (编辑:陈 宏)



          中国药房  2025年第36卷第18期                                              China Pharmacy  2025 Vol. 36  No. 18    · 2333 ·
   118   119   120   121   122   123   124   125   126   127   128